Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Medicinus : Jurnal Kedokteran
Kristin Talia Marbun
Department of Biology, Faculty of Science & Technology, Universitas Pelita Harapan, Tangerang 15811, Indonesia
Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
A Comparative Efficacy of Atezolizumab plus Bevacizumab Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Review Kristin Talia Marbun; Juandy Jo
Medicinus Vol 10, No 2 (2022): June 2022 - September 2022
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v10i2.5679

Abstract

Hepatocellular carcinoma (HCC) ranks sixth as the most common cancer and fourth as the most common cause of cancer-related death globally. The standard treatment for advanced HCC is by prescribing sorafenib, a tyrosine kinase inhibitor. Despite its moderate efficacy and concerning side effects, there is no better alternative to sorafenib to treat HCC. However, a new combination of atezolizumab (an inhibitor of PD-L1) and bevacizumab (an inhibitor of vascular endothelial growth factor), has shown a potential to surpass the efficacy of sorafenib. This review was written to provide an insight into pharmacodynamics of sorafenib and atezolizumab plus bevacizumab, effectiveness of sorafenib and the one of atezolizumab plus bevacizumab, utilization of atezolizumab plus bevacizumab in the clinical practice, as well as to argue that this combination can replace sorafenib as the standard palliative treatment for HCC.
Co-Authors Juandy Jo